Current and Future Disease Progression of the Chronic HCV Population in the United States

  title={Current and Future Disease Progression of the Chronic HCV Population in the United States},
  author={Martin Z{\'a}le{\vs}{\'a}k and Kevin M. Francis and Alex Gedeon and J Gillis and Kyle Hvidsten and Phyllis A. Kidder and Hong Li and Derek C. Martyn and Leslie S. Orne and Amanda Smith and Ann D. Kwong},
  journal={PLoS ONE},
Chronic hepatitis C virus (HCV) infection can lead to advanced liver disease (AdvLD), including cirrhosis, decompensated cirrhosis, and liver cancer. The aim of this study was to determine recent historical rates of HCV patient progression to AdvLD and to project AdvLD prevalence through 2015. We first determined total 2008 US chronic HCV prevalence from the National Health and Nutrition Evaluation Surveys. Next, we examined disease progression and associated non-pharmacological costs of… 

Figures and Tables from this paper

Universal screening for chronic hepatitis C virus

  • M. Shiffman
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2016
Universal screening for HCV would be optimal, however, the primary limitation once patients are identified is accessing treatment which remains restricted in most countries.

The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.

  • Z. YounossiL. Henry
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2014

Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis.

The disease burden associated with hepatitis C will continue to increase for most birth cohorts, likely peaking after age 70 years, and the substantial disease burden emerging in younger birth cohorts should be monitored.

Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia

In conclusion, productivity losses due to untreated HCV infection represent a substantial economic burden and by instituting universal HCV treatment with LDV/SOF (or other therapies with high SVR rates), productivity gains can be achieved.

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection.

The goals of current anti-HCV approaches are to cure infection, to prevent complications, and to prevent the spread of this disease to other individuals.

Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014

Direct-acting antiviral therapies are transforming how HCV is treated with significant improvements in efficacy and tolerability, and DAA agents expected to be available in 2014 are reviewed, including telaprevir, boceprevir, sofosbuvir, sime previr, faldaprevIR, and daclatasvir.

Improved survival outcomes in patients with non‐alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002–2012 United Network for Organ Sharing data

Despite having higher BMI and higher prevalence of diabetes and cardiac disease, patients with NASH had better post‐liver transplantation survival compared to patients with HCV or HCC, and patients with ALD also had superior survival outcomes.

Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.

2 first-generation protease inhibitors, telaprevir and boceprevir (also known as direct-acting antiviral drugs), were approved by the US Food and Drug Administration in 2011 and both agents offered significant efficacy in patients with HCV genotype 1 infection as measured by SVR rates.

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States

The number of CH-C patients 65 and older increased due to the aging of the baby boomer population and severity of illness and having private insurance were significantly associated with charge per hospital stay.

Hepatocellular carcinoma in patients with chronic hepatitis C: Experience gained at Clinical Center of Vojvodina

Etiology of every focal lesion in the liver must be clarified to increase the possibility of administration of available therapeutic methods in patients with chronic hepatitis C treated at the Clinical Centre of Vojvodina and therapy options.



Projecting future complications of chronic hepatitis C in the United States

  • G. DavisJ. AlbrightS. CookD. Rosenberg
  • Medicine, Biology
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C.

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

With the availability of effective highly active antiretroviral therapy for HIV infection, mortality from HIV appears to have declined substantially, whereas HCV‐related deaths as a result of pre‐1999 infections will likely continue to increase over the next 25’years.

Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

The high comorbidity burden of the hepatitis C virus infected population in the United States

Effective strategies to manage these comorbidities are necessary to allow wider access to HCV treatment and reduce the future burden of HCV disease and its manifestations.

Chronic hepatitis C: an age wave of disease burden.

Although it is difficult to predict which HCV-infected patients will progress to serious liver disease, the availability of a combination drug regimen that essentially "cures" the disease in more than half of treated patients now provides clinicians and pharmacists in managed care settings with the tools needed to diminish the impact of the anticipated wave of liver disease.

Estimating future hepatitis C morbidity, mortality, and costs in the United States.

The results confirm prior Centers for Disease Control and Prevention projections and suggest that HCV may lead to a substantial health and economic burden over the next 10 to 20 years.

The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007

By 2007, HCV had superseded HIV as a cause of death in the United States, and deaths from HCV and HBV disproportionately occurred in middle-aged persons, requiring new policy initiatives to detect patients with chronic hepatitis and link them to care and treatment.

Epidemiology of hepatitis C in the United States.

  • I. Williams
  • Medicine, Biology
    The American journal of medicine
  • 1999

Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population

Estimating all-cause and disease-related resource utilization and costs among managed care enrollees with chronic hepatitis C virus (HCV) found chronic HCV is a costly disease to managed care organizations and increased efforts in HCV screening and early treatment may lead to long-term cost savings.

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.